Work

In Search of the Best Way to Identify Those Who Would Benefit Most From COVID-19 Vaccination—Who Goes First?

Year: 2021

Type: article

Abstract: The rapid development of the COVID-19 vaccines and the excellent results from the phase 3 randomized clinical trials, which demonstrated approximately 95% efficacy of both mRNA vaccines for the prevention of severe laboratory-confirmed COVID-19 and even higher efficacy against severe disease and death from COVID-19, led the US Food and Drug Administration to grant both Pfizer-BioNTech and Moderna vaccines emergency use authorization in December 2020.

Source: JAMA Network Open

DOI: 10.1001/jamanetworkopen.2021.4623

Authors: Carlos del Rio, Saad Omer

Institutions: Emory University, Yale University

Language: English

Topic: SARS-CoV-2 and COVID-19 Research

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,000